Related Experiment Video
Updated: Jul 11, 2025
07:41
Behavioral Assessment of Visual Function via Optomotor Response and Cognitive Function via Y-Maze in Diabetic Rats
Published on: October 23, 2020
5.8K
Diabetic Retinopathy: A Pharmacological Consideration.
Saket Y Maheshwari1, Sunil Kumar1, Arya Harshyt Sinha2
1Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND.
Cureus
|November 13, 2023
Summary
Diabetic retinopathy (DR), an eye complication from diabetes, damages retinal blood vessels, potentially causing blindness. Anti-vascular endothelial growth factor (anti-VEGF) therapy offers improved vision with fewer side effects.
Area of Science:
- Ophthalmology
- Endocrinology
- Vascular Biology
Background:
- Diabetes mellitus (DM) is a global health issue, exacerbated in India by high-fat diets.
- Diabetic retinopathy (DR) is a severe complication of DM, causing retinal blood vessel damage due to hyperglycemia.
- DR is a leading cause of blindness, characterized by lesions in small blood vessels and symptoms like blurred vision and color distortion.
Purpose of the Study:
- To review current understanding and treatment of diabetic retinopathy (DR).
- To highlight the impact of DM and diet on DR prevalence.
- To discuss the efficacy of anti-vascular endothelial growth factor (anti-VEGF) therapy in managing DR.
Main Methods:
- Review of current medical literature on diabetic retinopathy.
- Analysis of existing treatment modalities including intravitreal injections, laser photocoagulation, and vitreous surgery.
- Focus on the mechanism and application of anti-VEGF therapy.
Main Results:
- DR poses a significant threat to vision, with lesions in retinal microvasculature as a diagnostic basis.
- Current treatments aim to prevent microvascular complications.
- Intravitreal anti-VEGF therapy is identified as a crucial treatment for optical improvement with reduced adverse effects.
Conclusions:
- Diabetic retinopathy is a major cause of blindness linked to diabetes and diet.
- Effective management strategies are essential to prevent vision loss.
- Anti-VEGF therapy represents a significant advancement in treating diabetic retinopathy.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
290
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
290
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
212
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
212
01:27Open Angle Glaucoma: Treatment
459
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
459
01:22Diabetes Mellitus: Type 2 and Gestational
2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
01:23Dipeptidyl Peptidase 4 Inhibitors
191
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
191
01:22Diabetes Mellitus: Overview and Type I Subtype
2.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.7K